Helper-Free Foamy Virus Vectors
- 20 November 1998
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 9 (17) , 2517-2525
- https://doi.org/10.1089/hum.1998.9.17-2517
Abstract
Retroviral vectors based on human foamy virus (HFV) have been developed and show promise as gene therapy vehicles. Here we describe a method for the production of HFV vector stocks free of detectable helper virus. The helper and vector plasmid constructs used both lack the HFV bel genes, so recombination between these constructs cannot create a wild-type virus. A fusion promoter that combines portions of the cytomegalovirus (CMV) immediate-early and HFV long terminal repeat (LTR) promoters was used to drive expression of both the helper and vector constructs. The CMV–LTR fusion promoter allows for HFV vector production in the absence of the Bel-1 trans-activator protein, which would otherwise be necessary for efficient transcription from the HFV LTR. Vector stocks containing either neomycin phosphotransferase or alkaline phosphatase reporter genes were produced by transient transfection at titers greater than 105 transducing units/ml. G418-resistant BHK-21 cells obtained by transduction with neo vectors contained randomly integrated HFV vector proviruses without detectable deletions or rearrangements. The vector stocks generated were free of replication-competent retrovirus (RCR), as determined by assays for LTR trans-activation and a marker rescue assay developed here for the detection of Bel-independent RCR. Vectors based on human foamy virus have been developed but low titers and the presence of replication-competent retrovirus (RCR) in vector stocks have prevented their use in preclinical animal experiments. We have developed a transient transfection method that can be used to produce replication-incompetent HFV vector stocks at titers greater than 105/ml, and that does not produce contaminating RCR. The use of CMV-HFV LTR fusion promoters in the helper and vector constructs has circumvented the requirement for the HFV Bel-1 trans-activator protein. Consequently, the potential for generating wild-type HFV by recombination between helper and vector constructs during vector production has been eliminated. Here we describe HFV vector production using this Bel-independent system.Keywords
This publication has 53 references indexed in Scilit:
- Foamy virus vectors for suicide gene therapyGene Therapy, 1997
- Gene Transfer Using Replication-Defective Human Foamy Virus VectorsVirology, 1997
- Expression of Human Foamy Virus Reverse Transcriptase Involves a Spliced pol mRNAVirology, 1996
- Human Foamy Virus Replication: A Pathway Distinct from That of Retroviruses and HepadnavirusesScience, 1996
- Replicating Foamy Virus-Based Vectors Directing High Level Expression of Foreign GenesVirology, 1995
- Markers of Foamy Virus Infections in Monkeys, Apes, and Accidentally Infected Humans: Appropriate Testing Fails to Confirm Suspected Foamy Virus Prevalence in HumansAIDS Research and Human Retroviruses, 1995
- Human foamy virus genome possesses an internal, Bel-1-dependent and functional promoter.Proceedings of the National Academy of Sciences, 1993
- Construction of an infectious DNA clone of the full-length human spumaretrovirus genome and mutagenesis of thebel 1 geneVirology, 1991
- The transcriptional transactivator of human foamy virus maps to the bel 1 genomic region.Proceedings of the National Academy of Sciences, 1991
- Polyoma transformation of hamster cell clones—an investigation of genetic factors affecting cell competenceVirology, 1962